🇺🇸 Belantamab Mafodotin-Blmf in United States
4 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 28 March 2025 – 28 March 2026
- Total reports: 4
Most-reported reactions
- Adverse Drug Reaction — 1 report (25%)
- Covid-19 — 1 report (25%)
- Infusion Related Reaction — 1 report (25%)
- Parainfluenzae Virus Infection — 1 report (25%)
Frequently asked questions
Is Belantamab Mafodotin-Blmf approved in United States?
Belantamab Mafodotin-Blmf does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Belantamab Mafodotin-Blmf in United States?
Hellenic Society of Hematology is the originator. The local marketing authorisation holder may differ — check the official source linked above.